The Second Affiliated Hospital of the Chinese Peoples' Liberation Army Air Form Medical University
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Echaniz-Laguna, Andoni
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28
THERAMAG, NCT05136976: Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders

Recruiting
3
90
Europe
Rituximab infusion, Mabthera, Placebo infusion, Sodium chloride (NaCl), Premedications
Centre Hospitalier Universitaire de Saint Etienne, Ministry of Health, France
Anti-MAG Neuropathy
12/25
12/25
NCT03943589 / 2018-001059-12: A Study of Imlifidase in Patients With Guillain-Barré Syndrome

Completed
2
30
Europe
Imlifidase, Hansa Medical-Immunoglobulin G degrading enzyme of Streptococcus pyogenes (HMED-IdeS), IdeS, IgG endopeptidase
Hansa Biopharma AB, Hansa Biopharma AB
Guillain-Barré Syndrome (GBS)
02/24
02/24
NERF-VASC, NCT05164822: Evolution of Neuropathies Associated With Necrotizing Vasculitis

Terminated
N/A
10
Europe
Necrotizing Vasculitis
Lille Catholic University, UNEOS
Necrotizing Vasculitis, Neuropathy
10/22
10/22
iMMersioN, NCT05988073: A Prospective Longitudinal Study in Adults with Multifocal Motor Neuropathy

Recruiting
N/A
150
Europe, Canada, Japan, US, RoW
argenx
Multifocal Motor Neuropathy
11/25
11/25
Bresch, Saskia
NCT06298552: A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

Recruiting
3
110
Europe, Canada, US, RoW
Efgartigimod IV, Placebo IV
argenx
Generalized Myasthenia Gravis
07/25
07/27
NIMBLE, NCT05070858 / 2020-003272-41: A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Recruiting
3
235
Europe, Canada, Japan, US, RoW
Pozelimab + Cemdisiran, Cemdisiran, ALN-CC5, Placebo, Pozelimab, REGN3918
Regeneron Pharmaceuticals
Generalized Myasthenia Gravis
05/25
03/28

Download Options